vs
渤健（BIIB）与凯旋（TFIN）财务数据对比。点击上方公司名可切换其他公司
凯旋的季度营收约是渤健的1.1倍（$2.4B vs $2.3B），凯旋净利率更高（0.3% vs -2.1%，领先2.4%），凯旋同比增速更快（2.6% vs -7.1%），过去两年凯旋的营收复合增速更高（377.6% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
凯旋汽车公司是19至20世纪活跃于英国的汽车与发动机制造企业，品牌起源可追溯到1885年。来自纽伦堡的齐格弗里德·贝特曼在伦敦成立公司，最初从欧洲进口自行车以自有商标销售，次年商标正式定为“凯旋”，1889年开始自主生产自行车。
BIIB vs TFIN — 直观对比
营收规模更大
TFIN
是对方的1.1倍
$2.3B
营收增速更快
TFIN
高出9.7%
-7.1%
净利率更高
TFIN
高出2.4%
-2.1%
两年增速更快
TFIN
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $2.4B |
| 净利润 | $-48.9M | $6.4M |
| 毛利率 | 78.3% | 86.1% |
| 营业利润率 | -2.5% | — |
| 净利率 | -2.1% | 0.3% |
| 营收同比 | -7.1% | 2.6% |
| 净利润同比 | -118.3% | -66.9% |
| 每股收益（稀释后） | $-0.35 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBTFIN
| Q1 26 | — | $2.4B | ||
| Q4 25 | $2.3B | $120.1M | ||
| Q3 25 | $2.5B | $109.3M | ||
| Q2 25 | $2.6B | $108.1M | ||
| Q1 25 | $2.4B | $101.6M | ||
| Q4 24 | $2.5B | $103.6M | ||
| Q3 24 | $2.5B | $106.2M | ||
| Q2 24 | $2.5B | $105.1M |
净利润BIIBTFIN
| Q1 26 | — | $6.4M | ||
| Q4 25 | $-48.9M | — | ||
| Q3 25 | $466.5M | $1.7M | ||
| Q2 25 | $634.8M | $4.4M | ||
| Q1 25 | $240.5M | $17.0K | ||
| Q4 24 | $266.7M | $3.8M | ||
| Q3 24 | $388.5M | $5.3M | ||
| Q2 24 | $583.6M | $2.7M |
毛利率BIIBTFIN
| Q1 26 | — | 86.1% | ||
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — |
营业利润率BIIBTFIN
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | — | ||
| Q3 25 | 22.0% | 1.2% | ||
| Q2 25 | 28.1% | 7.3% | ||
| Q1 25 | 12.8% | 0.1% | ||
| Q4 24 | 11.9% | 5.6% | ||
| Q3 24 | 18.3% | 5.9% | ||
| Q2 24 | 28.3% | 3.4% |
净利率BIIBTFIN
| Q1 26 | — | 0.3% | ||
| Q4 25 | -2.1% | — | ||
| Q3 25 | 18.4% | 1.6% | ||
| Q2 25 | 24.0% | 4.1% | ||
| Q1 25 | 9.9% | 0.0% | ||
| Q4 24 | 10.9% | 3.7% | ||
| Q3 24 | 15.8% | 5.0% | ||
| Q2 24 | 23.7% | 2.6% |
每股收益（稀释后）BIIBTFIN
| Q1 26 | — | $0.23 | ||
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $3.17 | $0.04 | ||
| Q2 25 | $4.33 | $0.15 | ||
| Q1 25 | $1.64 | $-0.03 | ||
| Q4 24 | $1.82 | $0.13 | ||
| Q3 24 | $2.66 | $0.19 | ||
| Q2 24 | $4.00 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | $6.3B | — |
| 股东权益账面价值 | $18.3B | $950.7M |
| 总资产 | $29.4B | $6.9B |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势，按日历期对齐
现金及短期投资BIIBTFIN
| Q1 26 | — | — | ||
| Q4 25 | — | $248.5M | ||
| Q3 25 | — | $147.2M | ||
| Q2 25 | — | $282.3M | ||
| Q1 25 | — | $502.9M | ||
| Q4 24 | — | $330.1M | ||
| Q3 24 | — | $489.3M | ||
| Q2 24 | — | $500.7M |
总债务BIIBTFIN
| Q1 26 | — | — | ||
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — |
股东权益BIIBTFIN
| Q1 26 | — | $950.7M | ||
| Q4 25 | $18.3B | $941.8M | ||
| Q3 25 | $18.2B | $919.3M | ||
| Q2 25 | $17.6B | $912.4M | ||
| Q1 25 | $17.0B | $893.9M | ||
| Q4 24 | $16.7B | $890.9M | ||
| Q3 24 | $16.4B | $885.8M | ||
| Q2 24 | $15.9B | $874.2M |
总资产BIIBTFIN
| Q1 26 | — | $6.9B | ||
| Q4 25 | $29.4B | $6.4B | ||
| Q3 25 | $29.2B | $6.4B | ||
| Q2 25 | $28.3B | $6.5B | ||
| Q1 25 | $28.0B | $6.3B | ||
| Q4 24 | $28.0B | $5.9B | ||
| Q3 24 | $28.3B | $5.9B | ||
| Q2 24 | $26.8B | $5.8B |
负债/权益比BIIBTFIN
| Q1 26 | — | — | ||
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | — |
| 自由现金流经营现金流 - 资本支出 | $468.0M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1B | — |
8季度趋势，按日历期对齐
经营现金流BIIBTFIN
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $67.1M | ||
| Q3 25 | $1.3B | $24.4M | ||
| Q2 25 | $160.9M | $9.8M | ||
| Q1 25 | $259.3M | $-3.6M | ||
| Q4 24 | $760.9M | $58.5M | ||
| Q3 24 | $935.6M | $26.6M | ||
| Q2 24 | $625.8M | $21.9M |
自由现金流BIIBTFIN
| Q1 26 | — | — | ||
| Q4 25 | $468.0M | — | ||
| Q3 25 | $1.2B | $22.4M | ||
| Q2 25 | $134.3M | $6.8M | ||
| Q1 25 | $222.2M | $-7.9M | ||
| Q4 24 | $721.6M | — | ||
| Q3 24 | $900.6M | $25.8M | ||
| Q2 24 | $592.3M | $-31.9M |
自由现金流率BIIBTFIN
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | — | ||
| Q3 25 | 48.4% | 20.5% | ||
| Q2 25 | 5.1% | 6.2% | ||
| Q1 25 | 9.1% | -7.7% | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 36.5% | 24.3% | ||
| Q2 24 | 24.0% | -30.3% |
资本支出强度BIIBTFIN
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.8% | 1.8% | ||
| Q2 25 | 1.0% | 2.8% | ||
| Q1 25 | 1.5% | 4.2% | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.4% | 0.8% | ||
| Q2 24 | 1.4% | 51.1% |
现金转化率BIIBTFIN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.73× | 14.29× | ||
| Q2 25 | 0.25× | 2.22× | ||
| Q1 25 | 1.08× | -212.82× | ||
| Q4 24 | 2.85× | 15.25× | ||
| Q3 24 | 2.41× | 4.97× | ||
| Q2 24 | 1.07× | 7.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
TFIN
暂无分部数据
